Objectives: Fifty patients enrolled in clinical trials with Immucothel((R)) were reevaluated for their disease-free intervals.
Methods: Of the 37 evaluable patients, 16 had received mitomycin C, 3 bacillus Calmette-Guérin, 3 Adriamycin and 15 miscellaneous pretreatments prior to Immucothel. They thus served as their own controls.
Results: Although their prognosis was worse at the time when Immucothel therapy was started than at the time of initiation of pretreatment, the mean recurrence-free intervals of all patients increased from 17.0 months under pretreatment to 35.1 months under Immucothel.
Conclusion: The difference was statistically significant (Wilcoxon matched-pairs signed-ranks test).
Copyright 2000 S. Karger AG, Basel